Agilent AdvanceBio Peptide Plus 2.7 μm Column for Peptide Characterization

Importance of Topic

Peptide mapping is a critical analytical approach for characterizing protein-based therapeutics and monitoring critical quality attributes (CQAs). High-resolution separation coupled with mass spectrometry is essential for identifying and quantifying peptides, but conventional sub-2 µm UHPLC columns often generate high operating backpressure. The AdvanceBio Peptide Plus 2.7 µm column bridges the gap, delivering near–UHPLC resolution with significantly reduced pressure, enabling compatibility with both HPLC and UHPLC platforms and lowering operational costs.

Objectives and Study Overview

This study evaluates the performance of the Agilent AdvanceBio Peptide Plus 2.7 µm, 2.1×150 mm column against a standard 1.7 µm CSH column under identical peptide mapping conditions. The goal is to compare peak capacity, backpressure, and peak efficiency (FWHM) during the analysis of a Lys C digest and a 25-peptide standard mix. Performance metrics and practical workflow compatibility were assessed to demonstrate operational benefits.

Methodology and Instrumentation

The columns were preconditioned with water–ACN gradients and equilibrated in 0.1% formic acid. A Lys C digest and a 25-peptide mix were injected in triplicate, with data from the third replicate used for analysis. Chromatographic conditions:

• System: Agilent 1260 Infinity II Bio-inert LC, 1290 binary pump, autosampler
• MS: Agilent 6550 Q-TOF using MassHunter Data Acquisition and Qualitative Analysis B.10
• Flow rate: 0.4 mL/min; temperature: 40 °C
• Mobile phases: 0.1% FA in water (A) and 0.1% FA in acetonitrile (B)
• Gradient: 0–2 min (97:3 A:B), 35 min (70:30), 40 min (3:97), 43 min (0:100), re-equilibration to 97:3 at 43.5 min

Key Results and Discussion

The AdvanceBio Peptide Plus column achieved a peak capacity of 223 and average FWHM of 0.0781, representing 91% of the performance of the 1.7 µm CSH column, which delivered a peak capacity of 246 and FWHM of 0.0729. Crucially, the operating backpressure for the 2.7 µm column was 326 bar, less than half of the 695 bar recorded for the sub-2 µm column. These results confirm that superficially porous particle technology enables high-resolution separations at reduced pressure, supporting both HPLC and UHPLC workflows.

Benefits and Practical Applications

The AdvanceBio Peptide Plus column offers:

• Near–UHPLC resolution with significantly lower backpressure
• Compatibility with existing HPLC and UHPLC systems to minimize equipment investments
• Reduced solvent consumption and maintenance costs
• Maintained peak efficiency for accurate peptide identification and quantitation

Future Trends and Opportunities

Further development of superficially porous particle chemistries may improve peak capacity and selectivity for complex proteomic analyses. Integration of these columns into high-throughput automated platforms can accelerate therapeutic protein characterization and support real-time quality control in biomanufacturing. Continued optimization of gradient conditions and coupling with ion mobility or advanced mass analyzers promises deeper proteome coverage.

Conclusion

The Agilent AdvanceBio Peptide Plus 2.7 µm column delivers a compelling balance between chromatographic resolution and operating pressure, achieving 91% of sub-2 µm performance at less than half the backpressure. Its platform versatility and cost-efficiency make it an attractive choice for peptide mapping and characterization in research and quality control laboratories.

References

No literature references were provided in the source document.